Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

410

HTML

3542

Figures (1-2)

127

Tables (1-1)

102

Sum=4181

Sep 15, 2003 (publication date) through Apr 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Sep 15, 2003; 9(9): 1959-1962
Published online Sep 15, 2003. doi: 10.3748/wjg.v9.i9.1959

Table 1 Informations of donors and their drug history

HH	Age (y)	Gender (F/M)	Drug history	Cell viability%
1	42	M	Fentanyl, ranitidine, dopamine	88
2	38	M	Vercuronium, fentanyl, ephedrine	86
3	18	M	Vasopressin, phenobarbital, rocuronium	90
4	26	F	Phenobarbital, fentanyl, vercuronium	92
5	39	F	Mlidozolam, fentanyl, lidocaine	80
6	54	M	Phenobarbital, rocuronium	84
7	49	M	Fentanyl, ephedrine	87
8	44	M	Fentanyl, ranitidine, dopamine	85

Citation: Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962
URL: https://www.wjgnet.com/1007-9327/full/v9/i9/1959.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i9.1959